Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Azeem Elbeih
Institution:
Mayo Clinic
Observed institution:
Mayo Clinic
OpenAlex ID:
A5115006556
Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating Agent
2024
·
Naseema Gangat
, Azeem Elbeih
, et al.
·
American Journal of Hematology
·
36
Predictors of post-transplant survival in patients with newly diagnosed acute myeloid leukemia receiving frontline venetoclax and hypomethylating agents.
2025
·
Isla Johnson
, Azeem Elbeih
, et al.
·
Journal of Clinical Oncology
·
1
TP53 mutations and Complex Karyotype in Newly-Diagnosed Blast/Accelerated Phase MPN Are Associated with Ephemeral Response to Treatment with Venetoclax + HMA and Poor Survival
2024
·
Naseema Gangat
, Kristen B. McCullough
, et al.
·
Blood
·
1
Response-Stratified Genetic Risk Model for Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent
2024
·
Naseema Gangat
, Azeem Elbeih
, et al.
·
Blood
Predictors of Relapse and Post-Relapse Outcomes in Patients with Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent
2024
·
Azeem Elbeih
, Nour Ghosoun
, et al.
·
Blood
PDF
Show more works
View as search
Works count:
5
Citation count:
38
H-index:
1
I10-index:
1
Year
Topic
Type
